Shearman & Sterling advised the underwriters of Caribou Biosciences, Inc.’s follow-on offering of 22,115,384 shares of common stock at a public offering price of $6.50 per share, resulting in gross proceeds to the Company of approximately $143.75 million, before deducting underwriting discounts and commissions and offering expenses.

BofA Securities, Leerink Partners, Evercore ISI and RBC Capital Markets acted as joint book-running managers for this offering.

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology toward the development of next-generation, genome-edited allogeneic immune cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors.  The therapies target cell surface antigens for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof-of-concept as well as additional emerging targets.

The Team